fenofibrate has been researched along with Overweight in 8 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effects of n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA), with those of fenofibrate, on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects." | 9.16 | Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects. ( Bragt, MC; Mensink, RP, 2012) |
| "To assess the effect of rimonabant, micronised fenofibrate and their combination on anthropometric and metabolic parameters in overweight/obese patients with dyslipidaemia." | 9.13 | Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. ( Elisaf, M; Filippatos, TD; Florentin, M; Kostara, C; Liberopoulos, EN; Mikhailidis, DP; Tselepis, A, 2008) |
| "We assessed the effect of orlistat and fenofibrate, alone or in combination, on plasma high-density lipoprotein (HDL) subfractions and plasma pre-beta1-HDL levels in overweight and obese subjects with metabolic syndrome (MetS)." | 9.13 | The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. ( Elisaf, MS; Filippatos, TD; Gazi, IF; Kiortsis, DN; Kostapanos, M; Liberopoulos, EN; Papavasiliou, EC; Tselepis, AD, 2008) |
| "The primary endpoint of this study was the effect of orlistat and fenofibrate, alone or in combination, on Lp-PLA(2) activity and LDL phenotype in overweight and obese patients (body mass index>28 kg/m(2)) with MetS." | 9.12 | The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. ( Athyros, VG; Elisaf, MS; Filippatos, TD; Gazi, IF; Kiortsis, DN; Liberopoulos, EN; Tselepis, AD, 2007) |
| "In an open-label randomised study (the FenOrli study) we assessed the effect of orlistat and fenofibrate treatment, alone or in combination on reversing the diagnosis of the MetS (primary end-point) as well as on anthropometric and metabolic parameters (secondary end-points) in overweight and obese patients with MetS but no diabetes." | 9.11 | Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. ( Elisaf, MS; Filippatos, TD; Georgoula, M; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP, 2005) |
| "Insulin sensitivity was unaffected by fenofibrate (P ≥ ." | 5.37 | Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans. ( Bergman, BC; Eckel, RH; Howard, DJ; Hunerdosse, DM; Perreault, L, 2011) |
| "To compare the effects of n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA), with those of fenofibrate, on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects." | 5.16 | Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects. ( Bragt, MC; Mensink, RP, 2012) |
| "To assess the effect of rimonabant, micronised fenofibrate and their combination on anthropometric and metabolic parameters in overweight/obese patients with dyslipidaemia." | 5.13 | Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. ( Elisaf, M; Filippatos, TD; Florentin, M; Kostara, C; Liberopoulos, EN; Mikhailidis, DP; Tselepis, A, 2008) |
| "We assessed the effect of orlistat and fenofibrate, alone or in combination, on plasma high-density lipoprotein (HDL) subfractions and plasma pre-beta1-HDL levels in overweight and obese subjects with metabolic syndrome (MetS)." | 5.13 | The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. ( Elisaf, MS; Filippatos, TD; Gazi, IF; Kiortsis, DN; Kostapanos, M; Liberopoulos, EN; Papavasiliou, EC; Tselepis, AD, 2008) |
| "The primary endpoint of this study was the effect of orlistat and fenofibrate, alone or in combination, on Lp-PLA(2) activity and LDL phenotype in overweight and obese patients (body mass index>28 kg/m(2)) with MetS." | 5.12 | The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. ( Athyros, VG; Elisaf, MS; Filippatos, TD; Gazi, IF; Kiortsis, DN; Liberopoulos, EN; Tselepis, AD, 2007) |
| "In an open-label randomised study (the FenOrli study) we assessed the effect of orlistat and fenofibrate treatment, alone or in combination on reversing the diagnosis of the MetS (primary end-point) as well as on anthropometric and metabolic parameters (secondary end-points) in overweight and obese patients with MetS but no diabetes." | 5.11 | Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. ( Elisaf, MS; Filippatos, TD; Georgoula, M; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP, 2005) |
| "Insulin sensitivity was unaffected by fenofibrate (P ≥ ." | 1.37 | Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans. ( Bergman, BC; Eckel, RH; Howard, DJ; Hunerdosse, DM; Perreault, L, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Michielsen, CCJR | 1 |
| Hangelbroek, RWJ | 1 |
| Bragt, MCE | 1 |
| Verheij, ER | 1 |
| Wopereis, S | 1 |
| Mensink, RP | 2 |
| Afman, LA | 1 |
| Montagner, A | 1 |
| Polizzi, A | 1 |
| Fouché, E | 1 |
| Ducheix, S | 1 |
| Lippi, Y | 1 |
| Lasserre, F | 1 |
| Barquissau, V | 1 |
| Régnier, M | 1 |
| Lukowicz, C | 1 |
| Benhamed, F | 1 |
| Iroz, A | 1 |
| Bertrand-Michel, J | 1 |
| Al Saati, T | 1 |
| Cano, P | 1 |
| Mselli-Lakhal, L | 1 |
| Mithieux, G | 1 |
| Rajas, F | 1 |
| Lagarrigue, S | 1 |
| Pineau, T | 1 |
| Loiseau, N | 1 |
| Postic, C | 1 |
| Langin, D | 1 |
| Wahli, W | 1 |
| Guillou, H | 1 |
| Florentin, M | 1 |
| Liberopoulos, EN | 4 |
| Filippatos, TD | 4 |
| Kostara, C | 1 |
| Tselepis, A | 1 |
| Mikhailidis, DP | 2 |
| Elisaf, M | 1 |
| Perreault, L | 1 |
| Bergman, BC | 1 |
| Hunerdosse, DM | 1 |
| Howard, DJ | 1 |
| Eckel, RH | 1 |
| Bragt, MC | 1 |
| Kiortsis, DN | 3 |
| Georgoula, M | 1 |
| Elisaf, MS | 3 |
| Gazi, IF | 2 |
| Athyros, VG | 1 |
| Tselepis, AD | 2 |
| Kostapanos, M | 1 |
| Papavasiliou, EC | 1 |
6 trials available for fenofibrate and Overweight
| Article | Year |
|---|---|
Comparative Analysis of the Effects of Fish Oil and Fenofibrate on Plasma Metabolomic Profiles in Overweight and Obese Individuals.
Topics: Double-Blind Method; Fatty Acids, Omega-3; Fenofibrate; Fish Oils; Humans; Obesity; Overweight; Trig | 2022 |
Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study.
Topics: Blood Pressure; Body Mass Index; Body Weight; Cardiovascular System; Female; Fenofibrate; Heart; Hum | 2008 |
Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Chemokine CCL2; Cholesterol, HDL; Cholesterol, LDL | 2012 |
Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Hum | 2005 |
The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Anti-Obesity Agents; Cardiovascular Diseases; | 2007 |
The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome.
Topics: Anti-Obesity Agents; Body Mass Index; Cholesterol, HDL; Drug Therapy, Combination; Female; Fenofibra | 2008 |
2 other studies available for fenofibrate and Overweight
| Article | Year |
|---|---|
Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.
Topics: Adipocytes; Aging; Animals; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Disease Models | 2016 |
Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans.
Topics: Aged; Blood Glucose; Body Composition; Female; Fenofibrate; Glucose Tolerance Test; Humans; Hypolipi | 2011 |